The profound impact on body weight and metabolic health have positioned GLP‐1 receptor agonists and their combinations as potentially transformative management options for obesity by safely and effectively closing the gap with the weight loss percentages usually achieved by BS (Figure 4). The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.